Literature DB >> 24726269

Translocation t(2;7)(p11;q21) associated with the CDK6/IGK rearrangement is a rare but recurrent abnormality in B-cell lymphoproliferative malignancies.

Nathalie Douet-Guilbert1, Corinne Tous2, Glen Le Flahec2, Clément Bovo3, Marie-Josée Le Bris2, Audrey Basinko2, Frédéric Morel1, Marc De Braekeleer4.   

Abstract

Structural abnormalities of chromosome 7q have been regularly reported in chronic B-cell lymphoproliferative disorders. They include chromosomal translocations involving 7q21, leading to overexpression of the CDK6 gene. Three different translocations, t(7;14)(q21;q32), t(7;22)(q21;q11), and t(2;7)(p11;q21), leading to the juxtaposition of the CDK6 gene with a immunoglobulin gene enhancer during B-cell differentiation, have been described. In the past 2 years, we identified three patients with lymphoproliferative malignancy associated with a t(2;7)(p11;q21). Fluorescent in situ hybridization using an IGK probe and a library of bacterial artificial chromosome (BAC) clones located in bands 7q21.2 and 7q21.3, containing CDK6, revealed that the telomeric part of the IGK probe was translocated on the der(7) within a 51-kb region upstream of the transcriptional start site of CDK6. A total of 23 patients with indolent B-cell lymphoproliferative disorders and juxtaposition of the IG and CDK6 genes, including 20 with IGK and CDK6 juxtaposition, have been reported thus far. This rearrangement leads to the overexpression of CDK6, which encodes a cyclin-dependent protein kinase involved in cell cycle G1 phase progression and G1/S transition.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B-cell lymphoproliferative malignancy; CDK6/IGK; chromosomal abnormality; t(2;7)(p11;q21)

Mesh:

Year:  2014        PMID: 24726269     DOI: 10.1016/j.cancergen.2014.02.009

Source DB:  PubMed          Journal:  Cancer Genet


  7 in total

1.  MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.

Authors:  Luciano Mazzoccoli; Marcela Cristina Robaina; Alexandre Gustavo Apa; Martin Bonamino; Luciana Wernersbach Pinto; Eduardo Queiroga; Carlos E Bacchi; Claudete Esteves Klumb
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-09       Impact factor: 4.553

2.  MicroRNA-related polymorphisms and non-Hodgkin lymphoma susceptibility in the Multicenter AIDS Cohort Study.

Authors:  Erin C Peckham-Gregory; Dharma R Thapa; Jeremy Martinson; Priya Duggal; Sudhir Penugonda; Jay H Bream; Po-Yin Chang; Sugandha Dandekar; Shen-Chih Chang; Roger Detels; Otoniel Martínez-Maza; Zuo-Feng Zhang; Shehnaz K Hussain
Journal:  Cancer Epidemiol       Date:  2016-10-01       Impact factor: 2.984

3.  H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma.

Authors:  Chao Li; Bingxi Lei; Shuaibin Huang; Meiguang Zheng; Zhenghao Liu; Zhongjun Li; Yuefei Deng
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

4.  Immunoglobulin gene translocations in chronic lymphocytic leukemia: A report of 35 patients and review of the literature.

Authors:  Marc DE Braekeleer; Corine Tous; Nadia Guéganic; Marie-Josée LE Bris; Audrey Basinko; Frédéric Morel; Nathalie Douet-Guilbert
Journal:  Mol Clin Oncol       Date:  2016-02-26

5.  Persistence of Breakage in Specific Chromosome Bands 6 Years after Acute Exposure to Oil.

Authors:  Alexandra Francés; Kristin Hildur; Joan Albert Barberà; Gema Rodríguez-Trigo; Jan-Paul Zock; Jesús Giraldo; Gemma Monyarch; Emma Rodriguez-Rodriguez; Fernanda de Castro Reis; Ana Souto; Federico P Gómez; Francisco Pozo-Rodríguez; Cristina Templado; Carme Fuster
Journal:  PLoS One       Date:  2016-08-01       Impact factor: 3.240

Review 6.  Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia.

Authors:  Patrizia Porazzi; Marco De Dominici; Joseph Salvino; Bruno Calabretta
Journal:  Genes (Basel)       Date:  2021-08-29       Impact factor: 4.096

Review 7.  Treating cancer with selective CDK4/6 inhibitors.

Authors:  Ben O'Leary; Richard S Finn; Nicholas C Turner
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.